PATENT ASSIGNMENT AGREEMENT
Exhibit 10.13
This PATENT ASSIGNMENT AGREEMENT is dated as of March 20, 2014 (this “Assignment”), by XXXXXXXX XXXXXXXXX, XXXXXX XXXXXXXXX, and XXXXX XXXX, individuals residing at 000 Xxxx 00xx Xxxxxx, Xxx 00X, Xxx Xxxx, XX 00000, 000 Xxxx 00xx Xx. Xxx 00X, Xxx Xxxx, XX 00000, and 00 Xxxxx Xxxx, Xxxxx, XX 00000 respectively (collectively “Assignors”), and FLEX PHARMA, INC., with offices at Prudential Tower, 000 Xxxxxxxx Xxxxxx, x/x Xxxxxxxx Xxxx, Xxxxxx, XX 00000 (“Assignee”).
1. Assignors hereby irrevocably convey, transfer, assign and deliver to Assignee, its successors and assigns, Assignors’ entire right, title and interest for the United States, its territories and possession, and all foreign countries in and to the Assigned Patents and all rights, claims and privileges pertaining thereto, including without limitation, all inventions and discoveries disclosed therein, certificates of invention and applications for certificates of invention, and any substitutions, reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations, continuations-in-part, continued prosecution applications, and corresponding foreign patents and patent applications and foreign counterparts thereof, and any and all rights to xxx and recover for claims and remedies against and collect damages and other recoveries for past, present and future infringements of any or all of the foregoing, and rights for priority and protection of interests therein under the laws of any jurisdiction and hereby grants to Assignee the right to apply, obtain and hold in its own name for patents or inventor’s certificates and related rights heretofore or hereafter filed in any and all countries, including, without limitation, the right to prosecute and maintain the same and all rights to claim priority based thereon, all patents granted thereon and all reissues, extensions and renewals thereof.
assign, deliver and communicate to Assignee, its representatives, agents, successors and assigns any facts and materials relating to the Assigned Patents, including evidence for interference purposes or for other legal proceedings whenever requested and all files, documents and communications pertaining to the Assigned Patents, including all communications to and from the U.S. Patent and Trademark Office and any and all legal counsel advising on or assisting with the Assigned Patents; (ii) to testify in any interference or other legal proceedings whenever requested; (iii) to execute and deliver whenever requested all lawful papers required to make any of the foregoing provisions effective; and (iv) to generally provide all further cooperation, including taking such further action and executing such additional documents, which Assignee, its successors and assigns requests to secure, obtain or enforce proper protection for the Assigned Patents and all associated rights in this or any foreign country.
7. Assignors hereby request and authorize Xxxxxx, LLP, 000 Xxxxxxxx Xx, Xxxxxx, XX 00000, to insert hereon any further identification information necessary or desirable for recordation of this document, including the filing date and application number of assigned applications or issued patents, if not yet known, when known.
(signature page follows)
ASSIGNEE: |
||
|
| |
|
| |
|
By: |
/s/ Xxxxx Xxxxxx |
|
Name: |
Xxxxx Xxxxxx |
|
Title: |
President |
[Signature Page to Patent Assignment Agreement]
SCHEDULE A
|
Country |
|
Title |
|
Application | |
Provisional |
|
US |
|
Methods and compositions for Relieving Muscle Cramps |
|
61/368,059 July 27, 2010 (expired) |
PCT |
|
WIPO |
|
Methods and Compositions for Preventing and Relieving Muscle Cramps and For Recovery from Neuromuscular Irritability and Fatigue Following Exercise |
|
PCT/US2011/045480 July 27, 2011 (abandoned) |
Nonprovisional |
|
US
|
|
Methods and Compositions for Preventing and Relieving Muscle Cramps and For Recovery from Neuromuscular Irritability and Fatigue Following Exercise |
|
13/191,941 July 27, 2011 (pending) |
National Stage |
|
EP |
|
Methods and Compositions for Preventing and Relieving Muscle Cramps and For Recovery from Neuromuscular Irritability and Fatigue Following Exercise |
|
11813088.9 (pending) July 27, 2011 |